Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

gastrointestinal therapeutics

- PMLiVE

Takeda and Zinfandel abandon Alzheimer’s drug

Pioglitazone failed to show therapeutic improvements in late-stage testing

- PMLiVE

Takeda bags EU approval for Adcetris in lymphoma

Data shows the drug improves PFS and symptom burden in CTCL patients

- PMLiVE

Novartis joins biosimilar Humira push in US

Pharma giant hopes its candidate will follow in the footsteps of Amgen’s Amjevita and BI’s Cyltezo

- PMLiVE

Takeda ties-up with Denali Therapeutics for neuroscience boost

The companies will develop new therapies for conditions such as Alzheimer’s

- PMLiVE

Takeda offers €520m for stem cell firm TiGenix

The deal will go ahead if the Japanese pharma company can secure an 85% stake in the biotech

- PMLiVE

AbbVie’s JAK inhibitor upadacitinib clears another phase III trial

Moves a step closer to the rheumatoid arthritis market

- PMLiVE

Takeda and SportInspired launch Active Communities, Brighter Future

The UK initiative will improve children's physical and mental wellbeing

EU flag

CHMP backs Europe’s first allogeneic stem cell therapy

Takeda has ex-US rights to the Crohn's disease treatment from biotech TiGenix

dengue fever mosquito

Sanofi confirms suspected safety issue with dengue vaccine

As rival Takeda conduct phase II testing for its own dengue vaccine candidate

J&J launches digital skincare challenge

Seeks start-ups focused on tackling areas such as skin health adherence treatment

EU flag

Janssen’s Tremfya cleared for European use

EC approves the medicine to treat adults with plaque psoriasis

- PMLiVE

EC expands Janssen’s prostate cancer drug reach

Zytiga plus predinson/prednisolone will now treat mHSPC patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links